A research study titled, “Schizophrenia Drugs Market by therapeutic class - global industry analysis and forecast to 2023” published by crystal market research.
Competitive InsightsThe leading players in the market are Eli Lilly and Company, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co Ltd, Vanda Pharma, Johnson & Johnson, Alkermes, Allergan and AstraZeneca. Johnson & Johnson, Otsuka and Lundbeck are concentrating on developing the schizophrenia therapeutics market for Long-Acting Injectables and are anticipated to possess tremendous position in the schizophrenia therapeutics market.
Industry Trend Analysis
The Schizophrenia Drugs Market was worth USD 6.35 billion in the year of 2014 and is expected to reach approximately USD 8.04 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 2.65% during the forecast period.
Schizophrenia is a chronic disorder of the central nervous system, influences 1.0% of the worldwide populace or seven out of 1,000 people. The confusion portrayed by side effects, for example, thought disorders, hallucinations, inability to execute day-to day functions is known to develop from a combination of chemical, environmental and genetic factors. Rising number of patients looking for treatment and rising interest for enhanced healthcare infrastructure are foreseen to drive the market. The schizophrenia market stays packed with solid neglected needs. There is a requirement for advancement for the treatment of this crippling disorder. The report examines about developing markets in the Asia Pacific region. India and China are rising as an open door for market extension. Factors, for example, useful medicinal services, increased health awareness, large aging population, and low-cost are the real driving variables for market extension in these two nations.
Request to access sample report here:www.crystalmarketresearch.com/report-sample/HC12414
Regional Outlook Japan is assessed to encounter the speediest development over the conjecture time frame because of enhanced healthcare infrastructure, increasing awareness about early diagnosis, rising disposable income, and accessibility of successful treatment. The worldwide schizophrenia drugs market will be driven by the developing awareness about mental issue, expanded use on medicinal services and accessibility of powerful treatment strategies with interest for tailored and target specific medications.
Market Segmentation- Schizophrenia Drugs Market
Schizophrenia Drugs Market, By Therapeutic Class, Estimates and Forecast, 2014-2023($Million)Second-Generation Antipsychotics
Invega (Paliperidone)
Geodon (Ziprasidone)
Latuda (Lurasidone)
Fanapt (Iloperidone)
Vraylar (Cariprazine)
Risperdal (Risperidone)
Zyprexa (Olanzapine)
Seroquel (Quetiapine)
Aristada (Aripiprazole Lauroxil)
Saphris (Asenapine)
Third-Generation Antipsychotics
Abilify (Aripiprazole)
Others
Generics
First-Generation Antipsychotics
Research Report Description with Detailed TOC on Schizophrenia Drugs Market @: www.crystalmarketresearch.com/report/schizophrenia-drugs-...
Schizophrenia Drugs Market, By Region, Estimates and Forecast, 2014-2023($Million) North America
U.S
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia Pacific
Rest of the World
Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others
Therapeutic Class Outlook and Trend AnalysisThe drugs that are prescribed for schizophrenia can be fragmented by therapeutic class into first, second and third-generation antipsychotics. Presently, second-generation and third-generation antipsychotics remain the standard of care in the schizophrenia treatment market. The report features brands recommended for the treatment of schizophrenia, for example, Saphris, Zyprexa, Abilify, Seroquel, Vraylar, Saphris, Aristada, Fanapt among others. Long-Acting Injectables (LAIs) are progressively being produced as they offer a few points of interest, for example, diminished hospitalizations and enhanced treatment result. The variables limiting the development of worldwide schizophrenia drugs market would be strict control around new product endorsements and rising generic dispatches.
Major Table of Contents:Chapter 1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
Chapter 2. Executive Summary
2.1. Key Highlights
Chapter 3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Rising Demand for Improved Healthcare Infrastructure
3.2.1.2. Growing Health Awareness
3.2.2. Restraints
3.2.2.1. Availability of Low Cost Substitute
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
....CONTINUED FOR TOC
To Avail Discount, Please click On the Link @www.crystalmarketresearch.com/check-discount/HC12414
About Crystal Market Research:
Crystal Offers One Stop Solution For Market Research, Business Intelligence, And Consulting Services To Help Clients Make More Informed Decisions. It Provides Both Syndicated As Well As Customized Research Studies For Its Customers Spread Across The Globe. The Company Offers Market Intelligence Reports Across A Broad Range Of Industries Including Healthcare, Chemicals & Materials, Technology, Automotive, And Energy.
Contact Us:
Judy S,
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: Sales@Crystalmarketresearch.Com
Competitive InsightsThe leading players in the market are Eli Lilly and Company, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co Ltd, Vanda Pharma, Johnson & Johnson, Alkermes, Allergan and AstraZeneca. Johnson & Johnson, Otsuka and Lundbeck are concentrating on developing the schizophrenia therapeutics market for Long-Acting Injectables and are anticipated to possess tremendous position in the schizophrenia therapeutics market.
Industry Trend Analysis
The Schizophrenia Drugs Market was worth USD 6.35 billion in the year of 2014 and is expected to reach approximately USD 8.04 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 2.65% during the forecast period.
Schizophrenia is a chronic disorder of the central nervous system, influences 1.0% of the worldwide populace or seven out of 1,000 people. The confusion portrayed by side effects, for example, thought disorders, hallucinations, inability to execute day-to day functions is known to develop from a combination of chemical, environmental and genetic factors. Rising number of patients looking for treatment and rising interest for enhanced healthcare infrastructure are foreseen to drive the market. The schizophrenia market stays packed with solid neglected needs. There is a requirement for advancement for the treatment of this crippling disorder. The report examines about developing markets in the Asia Pacific region. India and China are rising as an open door for market extension. Factors, for example, useful medicinal services, increased health awareness, large aging population, and low-cost are the real driving variables for market extension in these two nations.
Request to access sample report here:www.crystalmarketresearch.com/report-sample/HC12414
Regional Outlook Japan is assessed to encounter the speediest development over the conjecture time frame because of enhanced healthcare infrastructure, increasing awareness about early diagnosis, rising disposable income, and accessibility of successful treatment. The worldwide schizophrenia drugs market will be driven by the developing awareness about mental issue, expanded use on medicinal services and accessibility of powerful treatment strategies with interest for tailored and target specific medications.
Market Segmentation- Schizophrenia Drugs Market
Schizophrenia Drugs Market, By Therapeutic Class, Estimates and Forecast, 2014-2023($Million)Second-Generation Antipsychotics
Invega (Paliperidone)
Geodon (Ziprasidone)
Latuda (Lurasidone)
Fanapt (Iloperidone)
Vraylar (Cariprazine)
Risperdal (Risperidone)
Zyprexa (Olanzapine)
Seroquel (Quetiapine)
Aristada (Aripiprazole Lauroxil)
Saphris (Asenapine)
Third-Generation Antipsychotics
Abilify (Aripiprazole)
Others
Generics
First-Generation Antipsychotics
Research Report Description with Detailed TOC on Schizophrenia Drugs Market @: www.crystalmarketresearch.com/report/schizophrenia-drugs-...
Schizophrenia Drugs Market, By Region, Estimates and Forecast, 2014-2023($Million) North America
U.S
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia Pacific
Rest of the World
Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others
Therapeutic Class Outlook and Trend AnalysisThe drugs that are prescribed for schizophrenia can be fragmented by therapeutic class into first, second and third-generation antipsychotics. Presently, second-generation and third-generation antipsychotics remain the standard of care in the schizophrenia treatment market. The report features brands recommended for the treatment of schizophrenia, for example, Saphris, Zyprexa, Abilify, Seroquel, Vraylar, Saphris, Aristada, Fanapt among others. Long-Acting Injectables (LAIs) are progressively being produced as they offer a few points of interest, for example, diminished hospitalizations and enhanced treatment result. The variables limiting the development of worldwide schizophrenia drugs market would be strict control around new product endorsements and rising generic dispatches.
Major Table of Contents:Chapter 1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
Chapter 2. Executive Summary
2.1. Key Highlights
Chapter 3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Rising Demand for Improved Healthcare Infrastructure
3.2.1.2. Growing Health Awareness
3.2.2. Restraints
3.2.2.1. Availability of Low Cost Substitute
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
....CONTINUED FOR TOC
To Avail Discount, Please click On the Link @www.crystalmarketresearch.com/check-discount/HC12414
About Crystal Market Research:
Crystal Offers One Stop Solution For Market Research, Business Intelligence, And Consulting Services To Help Clients Make More Informed Decisions. It Provides Both Syndicated As Well As Customized Research Studies For Its Customers Spread Across The Globe. The Company Offers Market Intelligence Reports Across A Broad Range Of Industries Including Healthcare, Chemicals & Materials, Technology, Automotive, And Energy.
Contact Us:
Judy S,
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: Sales@Crystalmarketresearch.Com
No comments:
Post a Comment